image
Healthcare - Drug Manufacturers - General - NYSE - CH
$ 110.86
1.66 %
$ 219 B
Market Cap
18.89
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one NVS stock under the worst case scenario is HIDDEN Compared to the current market price of 111 USD, Novartis AG is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one NVS stock under the base case scenario is HIDDEN Compared to the current market price of 111 USD, Novartis AG is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one NVS stock under the best case scenario is HIDDEN Compared to the current market price of 111 USD, Novartis AG is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
51.7 B REVENUE
10.85%
14.5 B OPERATING INCOME
48.88%
11.9 B NET INCOME
39.28%
17.6 B OPERATING CASH FLOW
21.86%
-7.51 B INVESTING CASH FLOW
-134.26%
-11.7 B FINANCING CASH FLOW
17.76%
13.6 B REVENUE
2.93%
3.53 B OPERATING INCOME
-2.67%
2.82 B NET INCOME
-11.57%
4.19 B OPERATING CASH FLOW
-33.30%
-3.03 B INVESTING CASH FLOW
-710.96%
-3 B FINANCING CASH FLOW
-684.29%
Balance Sheet Novartis AG
image
Current Assets 29.7 B
Cash & Short-Term Investments 13.4 B
Receivables 9.54 B
Other Current Assets 6.81 B
Non-Current Assets 72.5 B
Long-Term Investments 1.13 B
PP&E 10.9 B
Other Non-Current Assets 60.5 B
Current Liabilities 28.7 B
Accounts Payable 4.57 B
Short-Term Debt 8.32 B
Other Current Liabilities 15.8 B
Non-Current Liabilities 29.4 B
Long-Term Debt 22.9 B
Other Non-Current Liabilities 6.49 B
EFFICIENCY
Earnings Waterfall Novartis AG
image
Revenue 51.7 B
Cost Of Revenue 12.8 B
Gross Profit 38.9 B
Operating Expenses 24.4 B
Operating Income 14.5 B
Other Expenses 2.6 B
Net Income 11.9 B
RATIOS
75.20% GROSS MARGIN
75.20%
28.12% OPERATING MARGIN
28.12%
23.09% NET MARGIN
23.09%
27.11% ROE
27.11%
11.68% ROA
11.68%
15.55% ROIC
15.55%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Novartis AG
image
Net Income 11.9 B
Depreciation & Amortization 6.07 B
Capital Expenditures -3.81 B
Stock-Based Compensation 1.04 B
Change in Working Capital -706 M
Others -1.87 B
Free Cash Flow 13.8 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Novartis AG
image
Wall Street analysts predict an average 1-year price target for NVS of $117 , with forecasts ranging from a low of $108 to a high of $121 .
NVS Lowest Price Target Wall Street Target
108 USD -2.58%
NVS Average Price Target Wall Street Target
117 USD 5.31%
NVS Highest Price Target Wall Street Target
121 USD 9.15%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
3.78 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Novartis AG
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for prostate cancer in vulnerable communities. youtube.com - 1 week ago
Novartis: Strong Execution With A P/E Discount Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and strategic investments in R&D confirmed our thesis on Novartis' new pure play as an innovative medicines leader. Novartis' strong FCF generation, supportive dividend yield, and ongoing buyback make it a buy. The company also trades below its peer average multiple. seekingalpha.com - 2 weeks ago
Novartis: Just What The Doctor Ordered Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost management drove a 15.1% sales increase and 29% EPS growth in Q4 2024. Novartis' shares are undervalued by 11%, offering a 33% cumulative return potential through 2027, with a secure and growing 3.5% dividend yield. seekingalpha.com - 2 weeks ago
Novartis to buy Anthos Therapeutics in $3.1bn deal Novartis AG (ADR) (NYSE:NVS) has agreed to buy Anthos Therapeutics in a deal worth up to $3.1 billion. The Swiss drugmaker will pay $925 million upfront, with potential milestone payments of $2.15 billion. proactiveinvestors.co.uk - 2 weeks ago
Novartis agrees to acquire Anthos for up to $3.1 bln Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant. reuters.com - 2 weeks ago
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The transaction, which is subject to customary closing conditions, is fully in line with Novartis' growth strategy and therapeutic area focus, leveraging the company's strength and expertise in the cardiovascular area. globenewswire.com - 2 weeks ago
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock? NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested. zacks.com - 3 weeks ago
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 3 weeks ago
Here's Why Novartis (NVS) is a Strong Value Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 3 weeks ago
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond If there were an official hierarchy of qualities that dividend seekers should consider before investing in a stock, a company's underlying business would almost certainly come ahead of its yield. However, the two aren't mutually exclusive. fool.com - 4 weeks ago
Novartis is considering further acquisitions to drive growth, CEO says Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the pharmaceutical industry, as well as the possibility of further acquisitions. youtube.com - 4 weeks ago
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company? zacks.com - 1 month ago
8. Profile Summary

Novartis AG NVS

image
COUNTRY CH
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 219 B
Dividend Yield 0.00%
Description Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Contact Lichtstrasse 35, Basel, 4056 https://www.novartis.com
IPO Date Nov. 7, 1996
Employees 75883
Officers Paul Penepent Head of Group Financial Reporting and Accounting Dr. Robert Kowalski Pharm.D. Chief People & Organization Officer Dr. Steffen Lang Ph.D. President of Operations Mr. Victor Bulto President of US Dr. Klaus Moosmayer Ph.D. Chief Ethics, Risk & Compliance Officer Ms. Karen L. Hale Chief Legal Officer Mr. Harry Kirsch Chief Financial Officer Dr. Patrick Horber M.D. President of International Dr. Vasant Narasimhan M.D. Chief Executive Officer Ms. Sloan Simpson Global Head of Investor Relations